• Mon, Mar. 20, 12:47 PM
    Mon, Mar. 20, 12:47 PM | 6 Comments
  • Fri, Mar. 17, 12:47 PM
    Fri, Mar. 17, 12:47 PM | 10 Comments
  • Fri, Mar. 17, 12:10 PM
    Fri, Mar. 17, 12:10 PM
  • Fri, Mar. 17, 9:09 AM
    • CLBS +53% on sale of 80.1% stake in its PCT subsidiary.
    • ABUS +14% on licensing deal with Alexion.
    • VIVE +6% on capital raise.
    • ADBE +5% on Q4 earnings.
    • ESEA +5% on improving shipping rates.
    Fri, Mar. 17, 9:09 AM | 2 Comments
  • Fri, Mar. 17, 8:23 AM
    • Alongside a Q4 earnings beat, the company last night announced the sale of its remaining 80.1% stake in its PCT subsidiary to Hitachi Chemical (which owns the other 19.9%) for $75M in cash. A revenue milestone could allow for another $5M payment.
    • Closing is expected in May.
    • Proceeds will be used to fund the Phase 2 trial for CLBS03, and the pay off the company's remaining $5.5M in outstanding debt.
    • A conference call is set for 8:30 ET.
    • CLBS +46% premarket
    Fri, Mar. 17, 8:23 AM | 1 Comment
  • Fri, Mar. 17, 7:01 AM
    • Caladrius Biosciences (NASDAQ:CLBS): Q4 EPS of -$0.73 beats by $0.07.
    • Revenue of $10.2M (+34.9% Y/Y) beats by $3.15M.
    • Press Release
    Fri, Mar. 17, 7:01 AM
  • Nov. 7, 2016, 4:34 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q3 EPS of -$1.09 beats by $0.46.
    • Revenue of $9.3M (+57.9% Y/Y) beats by $1.72M.
    • Press Release
    Nov. 7, 2016, 4:34 PM | 2 Comments
  • Sep. 19, 2016, 9:50 AM
    • Adaptimmune Therapeutics (ADAP +0.4%) announces that it has entered into a new five-year strategic manufacturing  agreement with PCT, a subsidiary of Caladrius Biosciences (NASDAQ:CLBS) for the supply of Adaptimmune’s SPEAR T-cell therapies. Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant manufacturing unit at PCT as well as dedicated, specialist staff.
    • Adaptimmune’s relationship with PCT, a contract manufacturer of patient cell therapy products, is intended to provide Adaptimmune with maximum operational flexibility for the manufacture of its SPEAR T-cell products from development, through clinical manufacturing and ultimately, subject to marketing authorizations, into commercialization.
    • Adaptimmune’s SPEAR T-cell therapies are novel cancer immunotherapies that use enhanced affinity T-cell receptors (TCRs) to target and destroy cancer cells by strengthening a patient’s natural T-cell response. T-cells are a type of white blood cell that play a central role in a person’s immune response to disease.
    Sep. 19, 2016, 9:50 AM | 2 Comments
  • Sep. 15, 2016, 12:56 PM
    Sep. 15, 2016, 12:56 PM | 3 Comments
  • Sep. 15, 2016, 8:47 AM
    • Caladrius Biosciences (NASDAQ:CLBS) enters into Securities Purchase Agreements with accredited investors for the direct sale of 4,449,153 shares of common stock at $4.72. Buyers include its largest institutional investor, Sanford Health, who invested $5M in the deal.
    • The $21M total investment will be made in two tranches: $12.6M no later than September 19 and $8.4M after the enrollment of 70 patients in the company's Phase 2 Sanford Project T-Rex Study of CLBS03 in adolescents with recent onset type 1 diabetes.
    • Net proceeds will fund T-Rex, principal and interest payments on its loan from Oxford Finance, LLC, working capital and general corporate purposes.
    • Yesterday's close was $4.34.
    • Previously: Caladrius Bio teams up with Sanford Research in diabetes (Sept. 22, 2015)
    Sep. 15, 2016, 8:47 AM
  • Aug. 26, 2016, 7:15 AM
    • Actinium Pharmaceuticals (NYSEMKT:ATNM) initiated with Buy rating and $5 (194% upside) price target by Roth Capital.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Neutral rating by Janney Montgomery Scott.
    • Cantel Medical (NYSE:CMN) initiated with Hold rating by Needham.
    • Patheon NV (Pending:PTHN) initiated with Outperform rating by William Blair.
    • Caladrius Biosciences (NASDAQ:CLBS) initiated with Buy rating and $6.50 (31% upside) price target by Chardan Capital.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) initiated with Buy rating and $5 (92% upside) price target by Rodman & Renshaw.
    • Rockwell Medical (NASDAQ:RMTI) initiated with Buy rating and $12 (72% upside) price target by BTIG Research.
    • Agios Pharmaceuticals (NASDAQ:AGIO) initiated with Neutral rating by BTIG Research.
    • TRACON Pharmaceuticals (NASDAQ:TCON) initiated with Buy rating and $15 (137% upside) price target by BTIG Research.
    • Ophthotech (NASDAQ:OPHT) initiated with Buy rating and $92 (76% upside) price target by BTIG Research.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) initiated with Neutral rating by BTIG Research.
    • Acceleron Pharma (NASDAQ:XLRN) initiated with Buy rating and $46 (55% upside) price target by BTIG Research.
    Aug. 26, 2016, 7:15 AM | 15 Comments
  • Aug. 9, 2016, 4:41 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q2 EPS of -$1.33 beats by $0.40.
    • Revenue of $8.3M (+41.4% Y/Y) beats by $0.77M.
    Aug. 9, 2016, 4:41 PM
  • May 5, 2016, 4:25 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q1 EPS of -$0.21 misses by $0.03.
    • Revenue of $7.49M (+136.3% Y/Y) misses by $0.28M.
    May 5, 2016, 4:25 PM | 7 Comments
  • Apr. 29, 2016, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    Apr. 29, 2016, 4:12 PM | 5 Comments
  • Mar. 15, 2016, 4:20 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q4 EPS of -$0.59 may not be comparable to consensus of -$0.28.
    • Revenue of $7.56M (+43.2% Y/Y) misses by $0.11M.
    Mar. 15, 2016, 4:20 PM
  • Mar. 14, 2016, 12:35 PM
    • Hitachi Chemical (OTCPK:HCHMY) establishes a 19.9% stake in Caladrius Biosciences (CLBS +16.8%) in conjunction with their global regenerative medicine collaboration. Under the terms of the partnership, Caladrius subsidiary PCT, LLC, will license its cell therapy technology and know-how to Hitachi for certain Asian territories, including Japan. Caladrius will receive an upfront payment and near-term milestones of $5.6M. Hitachi will pay service fees and royalties on contract revenue in its territories as well as all capital and operational expenses associated with ramping up the business on which PCT is entitled to royalties.
    • Hitachi and PCT are also mulling a joint venture in Europe.
    Mar. 14, 2016, 12:35 PM | 4 Comments